William Reardon - Tekla Healthcare Independent Trustees
| THQ Fund | USD 20.88 0.29 1.41% |
Mr. William S. Reardon, CPA is Independent Trustees of Tekla Healthcare Opportunities Fund. Until 2002, Mr. Reardon was a business assurance partner in PwC Boston office and leader of the Life Sciences Industry Practice for New England and the Eastern U.S., working closely with many of the Firm public clients in SECregistered equity, convertible and RD limited partnership offerings and many initial public offerings. He serves on the Valuation and Audit Committees of each Fund. From 19982000 he served on the Board of the Emerging Companies Section of the Biotechnology Industry Organization and from 2000 to 2002 he served on the Board of Directors of the Massachusetts Biotechnology Council . During his professional career, he was a frequent speaker at BIO conferences and MBC Industry meetings on issues affecting biotechnology companies. He currently also serves as a board member and audit committee chair of two developmentstage public companies, Synta Pharmaceuticals and Idera Pharmaceuticals
| Age | 74 |
| Tenure | 10 years |
| Professional Marks | CPA |
| Phone | 617 772 8500 |
| Web | https://www.teklacap.com/thq.html |
William Reardon Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Reardon against Tekla Healthcare fund is an integral part of due diligence when investing in Tekla Healthcare. William Reardon insider activity provides valuable insight into whether Tekla Healthcare is net buyers or sellers over its current business cycle. Note, Tekla Healthcare insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tekla Healthcare'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Reardon over two months ago Acquisition by William Reardon of 646 shares of Tekla Healthcare at 15.8551 subject to Rule 16b-3 | ||
William Reardon over three months ago Insider Trading |
Tekla Healthcare Management Performance (%)
Similar Money Managers
| Showing other executives | One Year Return | ||
| James Boyle | John Hancock Financial | 61 | |
| Lucinda Stebbins | Tekla Healthcare Investors | 73 | |
| Thomas Faust | Eaton Vance Tax | 63 | |
| Valerie Mosley | Eaton Vance Tax | 61 | |
| Francis Knox | John Hancock Financial | 73 | |
| Peter Hoglund | Royce Value Closed | 54 | |
| Roger Ko | Flaherty Crumrine Preferred | 45 | |
| Thomas Kent | Tekla Healthcare Investors | 67 | |
| Linda Puchalski | Flaherty Crumrine Preferred | 63 | |
| Rakesh Jain | Tekla Life Sciences | 69 | |
| Theron Hoffman | John Hancock Financial | 72 | |
| Salvatore Schiavone | John Hancock Financial | 55 | |
| Gregory Russo | John Hancock Financial | 71 | |
| Christopher Sechler | John Hancock Financial | 47 | |
| Peter Branner | Tekla Life Sciences | 60 | |
| William Cunningham | John Hancock Financial | 76 | |
| Deborah Jackson | John Hancock Financial | 68 | |
| Dr MS | Tekla Healthcare Investors | 71 | |
| Laura Woodward | Tekla World Healthcare | 51 | |
| Charles Bardelis | John Hancock Financial | 79 | |
| Lisa Curcio | Royce Value Closed | 60 | |
Tekla Healthcare Opp Leadership Team
Elected by the shareholders, the Tekla Healthcare's board of directors comprises two types of representatives: Tekla Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Healthcare's management team and ensure that shareholders' interests are well served. Tekla Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustees | ||
| Elizabeth Nabel, Independent Trustee | ||
| Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary | ||
| Lucinda Stebbins, Independent Trustees | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, President, Trustee | ||
| Rakesh Jain, Independent Trustees |
Tekla Fund Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right fund is not an easy task. Is Tekla Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Shares Outstanding | 41.34 M | |||
| Shares Owned By Institutions | 19.54 % | |||
| Number Of Shares Shorted | 14.15 K | |||
| Price To Earning | 6.76 X | |||
| Short Ratio | 0.14 X | |||
| Earnings Per Share | 2.71 X | |||
| Beta | 0.9 | |||
| Market Capitalization | 951.66 M | |||
| Annual Yield | 0.01 % | |||
| Year To Date Return | 10.58 % |
Pair Trading with Tekla Healthcare
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tekla Healthcare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tekla Healthcare will appreciate offsetting losses from the drop in the long position's value.Moving against Tekla Fund
| 0.71 | KINAX | Kinetics Internet | PairCorr |
| 0.71 | KINCX | Kinetics Internet | PairCorr |
| 0.69 | JPM | JPMorgan Chase Sell-off Trend | PairCorr |
| 0.68 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.66 | KNPCX | Kinetics Paradigm Steady Growth | PairCorr |
The ability to find closely correlated positions to Tekla Healthcare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tekla Healthcare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tekla Healthcare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tekla Healthcare Opportunities to buy it.
The correlation of Tekla Healthcare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tekla Healthcare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tekla Healthcare Opp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tekla Healthcare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Tekla Fund
Tekla Healthcare financial ratios help investors to determine whether Tekla Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tekla with respect to the benefits of owning Tekla Healthcare security.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |